Brokerages Set Morphosys AG (MOR) Target Price at $82.38
Morphosys AG (ETR:MOR) has been given a consensus rating of “Buy” by the eight research firms that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is €82.38 ($98.07).
MOR has been the subject of several analyst reports. Goldman Sachs Group set a €55.00 ($65.48) price target on shares of Morphosys and gave the company a “neutral” rating in a research note on Thursday, September 7th. Deutsche Bank set a €90.00 ($107.14) price target on shares of Morphosys and gave the company a “buy” rating in a research note on Thursday, September 7th. Commerzbank set a €76.00 ($90.48) price target on shares of Morphosys and gave the company a “buy” rating in a research note on Thursday, August 31st. J P Morgan Chase & Co reaffirmed a “buy” rating and set a price target on shares of Morphosys in a research note on Thursday, November 2nd. Finally, Independent Research set a €77.00 ($91.67) price target on shares of Morphosys and gave the company a “buy” rating in a research note on Thursday, September 7th.
Morphosys (ETR:MOR) traded down €1.16 ($1.38) during mid-day trading on Thursday, hitting €74.92 ($89.19). 133,622 shares of the stock traded hands, compared to its average volume of 153,640. Morphosys has a 12-month low of €44.75 ($53.27) and a 12-month high of €83.83 ($99.80).
WARNING: “Brokerages Set Morphosys AG (MOR) Target Price at $82.38” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.watchlistnews.com/brokerages-set-morphosys-ag-mor-target-price-at-82-38/1770227.html.
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for Morphosys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphosys and related companies with Analyst Ratings Network's FREE daily email newsletter.